Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Changing home designs and materials to make homes cooler and harder for mosquitoes to enter could reduce malaria transmission in sub-Saharan Africa, according to a new study in The Lancet Planetary Health.

Study researchers found 96% fewer mosquitoes in a Southeast Asian style two storey house built with permeable local bamboo walls and screened windows compared to a traditional mud or wattle-daub African home built on the ground with poor ventilation.

“New house designs could become an important health intervention in the fight against malaria in Africa,” said Dr Lorenz von Seidlein, study author and Head of Targeted Malaria Elimination at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand.

“Between 80-100% of malaria transmission there occurs indoors at night, yet people often don’t sleep under insecticide-treated bednets because they are uncomfortably hot. We think there is an unprecedented opportunity to fight malaria transmission in hot, humid Sub-Saharan Africa by designing homes that keep the cool in and mosquitoes out,” said Dr von Seidlein.

Funded by the Ruth W Jensens Foundation, Denmark, and the Hanako Foundation, Singapore, the study built six prototype houses based on a Southeast Asian design in the village of Magoda in Muheza District, Tanga Region, Tanzania, and compared them with modified and unmodified traditional, sub-Saharan African houses.

The prototype houses were designed by Prof Jakob Knudsen of the University of Copenhagen School of Architecture (KADK) and owner of Ingvartsen, a practice in Copenhagen. In June 2015, long-time Shoklo Malaria Research Unit (SMRU) staff member Mr. Tip Ruechaitrakul, two Karen colleagues and a local Tanzanian craftsman built a typical two storey Thai-Karen house that was included the study and found to have the best climate comfort index of all study houses.

Researchers found that while both Southeast Asia style single and two storey buildings provided a cooler indoor climate than traditional housing, two-storey buildings provided the biggest reduction in mosquito densities, with 96% fewer mosquitoes than in a traditional African home.

“Our next step is a randomised trial to prove (or disprove) whether the findings hold in a substantial number of African houses and villages. We are looking for funding for a household randomised cohort trial where 110 households receive a novel design home and are compared with a cohort of residents living in 440 traditional, rural African homes,” said Dr von Seidlein.

Study reference (an error-free, updated version should be available 4 Sept 2017)

Affordable house designs to improve health in rural Africa: a field study in northeastern Tanzania. von Seidlein L, Ikonomidis K, Mshamu S, Nkya TE, Mukaka M, Pell C, Lindsay SW, Deen JL, Kisinza WN, Knudsen JB. The Lancet Planetary Health, vol 1, No. 5, e188-e199, Aug 2017. DOI: http://dx.doi.org/10.1016/S2542-5196(17)30078-5. http://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(17)30078-5/fulltext

Similar stories

Researchers call for access to Ivermectin for young children

MORU Bangkok Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

MORU Bangkok Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

MORU Bangkok

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.